

ASX Announcement

Bisantrene shows potent anticancer activity in diverse cell and animal models of Acute Myeloid Leukemia

- Bisantrene shows potent activity in a range of patient-derived primary acute myeloid leukemia (AML) cells and in mouse models of AML
- The combination of bisantrene and decitabine exhibits robust anticancer synergy in both cell and mouse AML models
- Key cellular pathways targeted by bisantrene were identified, further supporting the use of bisantrene in combination with decitabine as a low intensity treatment for AML patients.

06 March 2024 – Race Oncology Limited (“Race”) scientists, in collaboration with researchers from the University of Newcastle (Newcastle, Australia), presented results from pre-clinical studies exploring the use of bisantrene, both as a single drug and in combination with decitabine, as a new treatment for acute myeloid leukemia (AML) at the *New Directions in Leukaemia Research* conference in Adelaide (March 4-6, 2024).

The poster presentation entitled “*Preclinical evaluation of bisantrene alone and in combination with decitabine for Acute Myeloid Leukemia*” demonstrates that bisantrene is highly effective at killing patient-derived AML cancer cells *in vitro* and *in vivo* as a single agent and showed significantly higher anticancer activity (p-value < 0.001) when used in combination with the standard of care drug, decitabine. Key cellular pathways targeted by the synergistic combination of bisantrene and decitabine were also identified in the work.

The preclinical data are highly supportive of clinical trials of Race’s new bisantrene formulation (RC220) combined with oral decitabine, as a low intensity treatment approach, for AML patients. Data from this study is expected to be submitted for publication in a high-impact peer reviewed journal in 2024.

The poster presentation is attached to this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

Joshua S Brzozowski^{1,2}, Nikita Panicker^{1,2}, Kasey Miller^{1,2}, Marinella Messina³, Benjamin J Buckley³, Michael J Kelso³, Daniel Tillett³, Anoop K Enjeti^{4,5} and Heather C Murray^{1,2} Nicole M Verrills^{1,2}

1. School of Biomedical Sciences and Pharmacy, College of Health, Medicine & Wellbeing, University of Newcastle, NSW, Australia
2. Precision Medicine Program, Hunter Medical Research Institute, Newcastle, NSW, Australia
3. Race Oncology Limited, Sydney, NSW, Australia;

4. Calvary Mater Hospital, Newcastle, 2298, NSW, Australia
5. School of Medicine and Public Health, College of Health, Medicine & Wellbeing, University of Newcastle, NSW, Australia
Contact: niki.verrills@newcastle.edu.au

INTRODUCTION

Acute Myeloid Leukaemia (AML) is the most lethal form of leukaemia, carrying a 5-year survival rate of 24%. Anthracyclines (e.g. daunorubicin and idarubicin) together with cytarabine comprise standard of care induction chemotherapy in acute myeloid leukaemia (AML). Although 60% of patients achieve remission, the majority relapse within 1-2 years, with overall 5-year survival only 27%. Toxicity of induction therapy is a major barrier to treatment success, precluding many unfit and elderly patients. Hypomethylating agents (HMA; azacitidine, decitabine) provide a less toxic alternative and have improved treatment options for the unfit, however, most eventually acquire resistance resulting in relapse.


Bisantrene is an anthracene derivative originally developed as a less cardiotoxic chemotherapy alternative to anthracyclines. Clinical studies showed bisantrene is an effective AML salvage therapy, producing response rates up to 50% without accompanying cardiotoxicity (Rothman 2017 *Int J Cancer Res Ther*, 2, 1-10). Bisantrene has also been reported to inhibit FTO, an RNA N⁶-methyladenosine (m⁶A) demethylase, that plays oncogenic roles in various cancers, including AML, and FTO inhibition sensitizes AML cells to HMAs (Su *et al.*, 2020 *Cancer Cell* 38, 79-96).

Therefore, we hypothesized that bisantrene may sensitize AML cells to HMAs, and thus provide an alternative chemotherapeutic option in combination with HMAs for AML therapy.

RESULTS


1. Bisantrene shows single agent activity in AML

- Bisantrene inhibits growth (Fig 1A) and induces apoptosis (Fig 1B) of AML cell lines.




- Bisantrene displays variable single agent efficacy against primary AML bone marrow derived mononuclear cells *ex vivo* (Fig 2).

- Correlation with mutation status revealed NPM1^{mut} AML were more sensitive to bisantrene than NPM1^{WT} *ex vivo* (p<0.05). KRAS, ASXL1 and TET2 mutant AMLs showed a trend towards higher bisantrene sensitivity.



- Bisantrene produces a dose-dependent increase in survival of mice engrafted with AML cell line or patient-derived xenografts (Fig. 3).




▲ Figure 3. Bisantrene increases survival of mice engrafted with AML. A) NSG mice were engrafted with MOLM-13-luc cells and leukaemia burden monitored by bioluminescence imaging. Bisantrene was administered three times per week at 5mg/kg or 10mg/kg for up to 3 weeks. B) PDX-AML16 cells were engrafted into NSG mice and once human CD45+ cells reached ~1% in the peripheral blood, mice were randomised and treated with vehicle control, 2.5mg/kg or 5mg/kg i.v. bisantrene (Bis) 3 t.i.w. as indicated (grey shading). Mice were sacrificed when the percentage of human CD45+ cells in the peripheral blood reached 25% (determined by flow cytometry). Kaplan-Meier survival curve. n≥5 mice/group. Median survival in days shown. **p<0.01.

2. Bisantrene enhances the effects of decitabine *in vitro*


- AML cells pre-treated with decitabine for 1 day, followed by decitabine plus bisantrene for 3 days, induced synergistic cytotoxicity at multiple doses for all cells (Fig. 4A).

- MOLM13 cells displayed the highest overall synergy (Fig. 4B).



▲ Figure 4: Bliss Synergy Analysis. Cells were pre-treated with decitabine for 24hrs, then bisantrene plus decitabine for 72hr at indicated doses. A) 3D visualization of predicted Bliss scores at each dose point, with red to green scale indicating areas of synergy to antagonism, and the average synergy score. B) Table of Bliss scores for the average across all doses, and the most synergistic 2x2 area. Values >10 are considered synergistic (red); below -10 antagonistic; and between -10 to 10 are additive.

- Combined decitabine and bisantrene induces more apoptosis than either drug alone (Fig. 5).



► Figure 5. Decitabine and bisantrene induce apoptosis in AML cells. Cells were pre-treated with decitabine (DAC) for 1 day, then Bisantrene plus Decitabine for 2 days at indicated doses Apoptosis was measured by Annexin V/PI flow cytometry assay.

AIMS

- Test the efficacy of the bisantrene/decitabine combination *in vitro* and *in vivo*.
- Investigate the mechanism of action of bisantrene and decitabine.

METHODS

- The *in vitro* activity of bisantrene +/- decitabine was assessed in range of AML cell lines using resazurin assays and the combination effect determined using Bliss synergy analysis.
- The effect of bisantrene +/- decitabine on apoptosis was assessed by Annexin V/propidium iodide flow (PI) cytometry assays.
- The *ex vivo* sensitivity of primary AML patient bone marrow-derived mononuclear cells was determined using an ATP life assay.
- The *in vivo* efficacy of bisantrene +/- decitabine was assessed in NSG mice engrafted with MOLM13-luc AML cells, or an AML patient derived xenograft (PDX-AML16, originally isolated from a 61yo female with AML M4 subtype, with normal cytogenetics, FLT3-TD⁺ mutant IDH2 (R140Q), NPM1 and WT1 (Lee *et al Haematologica* 100, 914-926).
- The effect of bisantrene +/- decitabine on the proteome and phosphoproteome was investigated using label-free quantitative mass spectrometry and gene-set and ingenuity pathway analyses.

3. Bisantrene enhances the efficacy of decitabine *in vivo*

- The effect of combining bisantrene with two different decitabine dosing regimens was tested in the MOLM13 cell line mouse model (Fig. 6).

- Administration of either 0.5 mg/kg decitabine for 5 days only; or 0.2 mg/kg decitabine 5 days/week for 3 weeks, reduced leukaemic burden and enhanced the survival alone.

- The combination of bisantrene and decitabine showed significantly higher efficacy than either drug alone in both experiments.





Figure 6. *In vivo* efficacy of combined bisantrene and decitabine. MOLM13 cells were engrafted into NSG mice and treated with vehicle, 0.2mg/kg i.p. decitabine (A-C) or 0.5mg/kg i.p. decitabine for 5 days (D-F). i.v. bisantrene, as indicated. Leukaemia burden was detected by bioluminescence imaging (BLI) at indicated intervals. A-D) Study design. B-E) Quantitation of BLI; mean +/- SEM. C-F) Kaplan-Meier survival curve. n=10 mice/group. C) Median survival for vehicle =18; decitabine = 21; bisantrene = 23; Combined drugs = 30 days. F) Median survival for vehicle =18; decitabine = 20; bisantrene = 23; Combined drugs = 26 days ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05.

- The combination of bisantrene and decitabine also showed significantly higher efficacy than either drug alone in the PDX-AML16 mouse model (Fig. 7).



▲ Figure 7. *In vivo* efficacy of combined bisantrene and decitabine in a patient derived AML xenograft. PDX-AML16 cells were engrafted into NSG mice and once human CD45+ cells reached ~1% in the peripheral blood, mice were randomised and treated with vehicle control, 0.2mg/kg i.p. decitabine (DAC) 5 t.i.w. 5mg/kg i.v. bisantrene (Bis) 2 t.i.w., or both drugs, for 4 weeks as indicated (grey shading). Mice were sacrificed when the percentage of human CD45+ cells in the peripheral blood reached 25% (determined by flow cytometry). A) Study design. B) Leukaemic burden over time for individual animals. C) Kaplan-Meier survival curve. n=7 mice/group. Median survival for vehicle = 36; decitabine = 86; bisantrene = 56; Combined decitabine + bisantrene = 111 days. ***p<0.001; *p<0.05.


4. Key cellular pathways targeted by combined bisantrene and decitabine

- Differential proteomic and gene set enrichment analysis was used to compare the three most bisantrene-sensitive versus least sensitive cell lines (Fig 1A). Increased expression of MYC targets, G2M checkpoint, MTORC and E2F targets were associated with bisantrene sensitivity (Fig. 8A).

- Phosphoproteomic analysis of MOLM13 cells treated with decitabine +/- bisantrene identified inhibition of MYC, MTOR and RhoA signalling & activation of DNA damage repair and the UPR (Fig. 8B)

- Inhibition of MYC and MTOR signalling are likely key drivers of the anti-leukaemic effect of combined decitabine and bisantrene in AML.

- Figure 8: Proteome/Phosphoproteome Pathway Analysis. A) Proteome analysis of the three most and least bisantrene-sensitive AML cell lines was performed by quantitative mass spectrometry. Differentially expressed proteins were analysed by GSEA and significantly enriched pathways identified. NES, normalised enrichment scores. B) Phosphoproteome analysis of MOLM13 cells treated with 50nM decitabine (DAC) 48hr, 50nM bisantrene (Bis) 24hr, or the combination of both drugs. Phosphopeptides significantly enriched with treatments were analysed by IPA to identify enriched pathways. The predicted activation score indicates pathway inhibition (blue) or activation (red).



Conclusion: Combining bisantrene and decitabine is a potential therapeutic strategy for AML therapy

Acknowledgements:

We thank Prof Richard Lock and Dr Charles de Bock, Children's Cancer Institute Australia, for providing AML-PDXs and the MOLM13-luc cells, respectively.

Funding:

RACE ONCOLOGY

